# Mary McCormack

Source: https://onco.cc/people/mary-mccormack/  
OnCo record `mary-mccormack` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led INTERLACE, which showed a short course of chemotherapy before chemoradiation cuts cervical cancer deaths using cheap, available drugs.

## Summary

Mary McCormack was chief investigator of INTERLACE, the international trial showing six weeks of induction carboplatin and paclitaxel before standard chemoradiotherapy improves progression-free and overall survival in locally advanced cervical cancer, a result immediately implementable in low-resource settings where most cervical cancer occurs. She leads gynaecological radiotherapy research at UCLH.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: cervical; chemoradiotherapy; global-health
- Role: Consultant Clinical Oncologist, University College London Hospitals
- Specialisms: Cervical cancer; Chemoradiotherapy; Induction chemotherapy; Gynaecological radiotherapy

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=McCormack%20M%5BAuthor%5D%20INTERLACE%20cervical

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- technologies: [Brachytherapy](https://onco.cc/technologies/brachytherapy/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- institutions: [University College London Hospitals / UCL Cancer Institute](https://onco.cc/institutions/uclh/)
- trials: [INTERLACE](https://onco.cc/trials/interlace/)
- journals: [British Journal of Cancer](https://onco.cc/journals/british-journal-of-cancer/)

---
JSON: https://onco.cc/api/v1/entities/mary-mccormack.json